A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease

Pfeffer, Marc A., Burdmann, Emmanuel A., Chen, Chao-Yin, Cooper, Mark E., de Zeeuw, Dick, Eckardt, Kai-Uwe, Feyzi, Jan M., Ivanovich, Peter +11 more·2009·New England Journal of Medicine
DOI 10.1056/nejmoa0907845

Cited by (1,000)

Items 601–700 of 1,000

  1. The impacts of hypoxia-inducible factor stabilizers on laboratory parameters and clinical outcomes in chronic kidney disease patients with renal anemia: a systematic review and meta-analysis
    Kullaya Takkavatakarn, Theerachai Thammathiwat, Jeerath Phannajit, Pisut Katavetin, Kearkiat Praditpornsilpa, Somchai Eiam‐Ong, Paweena Susantitaphong · 2023 · Clinical Kidney Journal
  2. Safety of Roxadustat Versus Erythropoiesis-Stimulating Agents in Patients with Anemia of Non-dialysis-Dependent or Incident-to-Dialysis Chronic Kidney Disease: Pooled Analysis of Four Phase 3 Studies
    Jonathan Barratt, Frank Dellanna, José María Portolés, Gabriel J. Choukroun, Luca De Nicola, James Young, Nada B. Dimkovic, Michael Reusch · 2023 · Advances in Therapy
  3. KHA‐CARI Guideline: Use of iron in chronic kidney disease patients
    Rob MacGinley, Rowan G. Walker, Michelle J. Irving · 2013 · Nephrology
  4. Pathophysiologic and Treatment Strategies for Cardiovascular Disease in End-Stage Renal Disease and Kidney Transplantations
    Mythili Ghanta, Mark Kozicky, Belinda Jim · 2014 · Cardiology in Review
  5. Randomized Controlled Trials in Nephrology: State of the Evidence and Critiquing the Evidence
    Joshua Samuels, Donald A. Molony · 2012 · Advances in Chronic Kidney Disease
  6. Perceptions and use of the national kidney foundation KDOQI guidelines: a survey of U.S. renal healthcare providers
    Michelle M. Estrella, Bernard G. Jaar, Kerri L. Cavanaugh, Chester H. Fox, Mark Anthony Perazella, Sandeep S. Soman, Emily Howell, Michael V. Rocco, Michael Jin Choi · 2013 · BMC Nephrology
  7. Management of the Diabetic Patient with Advanced Chronic Kidney Disease
    Radica Z. Alicic, Katherine R. Tuttle · 2010 · Seminars in Dialysis
  8. Anemia in chronic kidney disease patients: treatment recommendations and emerging therapies
    Lucia Del Vecchio, Francesco Locatelli · 2014 · Expert Review of Hematology
  9. ANAEMIA, DIABETES AND CHRONIC KIDNEY DISEASE: WHERE ARE WE NOW?
    Paul E. Stevens · 2012 · Journal of Renal Care
  10. Trends in Anemia Management Practices in Patients Receiving Hemodialysis and Peritoneal Dialysis: A Retrospective Cohort Analysis
    James B. Wetmore, Yi Peng, Keri L. Monda, Allyson M. Kats, Deborah H. Kim, Brian D. Bradbury, Allan J. Collins, David T. Gilbertson · 2015 · American Journal of Nephrology
  11. The Relationship of Initial Transferrin Saturation to Cardiovascular Parameters and Outcomes in Patients Initiating Dialysis
    Hyang Mo Koo, Chan Ho Kim, Fa Mee Doh, Mi Jung Lee, Eun Jin Kim, Jae Hyun Han, Ji Suk Han, Hyung Jung Oh, Jung Tak Park, Seung Hyeok Han et al. · 2014 · PLoS ONE
  12. Transfusion-induced HLA sensitization in wait-list patients and kidney transplant recipients
    Michelle Kay Willicombe, David J. Roberts · 2024 · Kidney International
  13. Blood transfusions in kidney transplant candidates are common and associated with adverse outcomes
    Hassan N. Ibrahim, Melissa A. Skeans, Qi Li, Areef Ishani, Jon J. Snyder · 2011 · Clinical Transplantation
  14. Impact of frequent hemodialysis on anemia management: results from the Frequent Hemodialysis Network (FHN) Trials
    Daniel B. Ornt, Brett Larive, Anjay Rastogi, Mohamad A. Rashid, John T. Daugirdas, Ann Hernandez, Manjula Kurella Tamura, Rita S. Suri, Nathan W. Levin, Alan S. Kliger et al. · 2013 · Nephrology Dialysis Transplantation
  15. 2009
    David J.A. Goldsmith · 2010 · Clinical Journal of the American Society of Nephrology
  16. Erythropoietin in the intensive care unit: beyond treatment of anemia
    Nimesh S. A. Patel, Massimo Collino, Muhammad Magdi Yaqoob, Christoph Thiemermann · 2011 · Annals of Intensive Care
  17. Lessons Learned from EVOLVE for Planning of Future Randomized Trials in Patients on Dialysis
    Patrick S. Parfrey, Geoffrey A. Block, Ricardo Correa‐Rotter, Tilman Bernhard Drüeke, Jürgen Floege, Charles A. Herzog, Gerard Michel London, Kenneth W. Mahaffey, Sharon M. Moe, David Collins. Wheeler et al. · 2015 · Clinical Journal of the American Society of Nephrology
  18. Iron Therapy Challenges for the Treatment of Nondialysis CKD Patients
    Francesco Locatelli, Sandro Mazzaferro, Jerry Yee · 2016 · Clinical Journal of the American Society of Nephrology
  19. Precision Nephrology Is a Non-Negligible State of Mind in Clinical Research: Remember the Past to Face the Future
    Michele Provenzano, Luca De Nicola, Michelle J. Pena, Giulia Capitoli, Carlo Garofalo, Silvio Borrelli, Ida Gagliardi, Laura Antolini, Michele Andreucci · 2020 · The Nephron journals/Nephron journals
  20. Factors affecting the doses of roxadustat vs darbepoetin alfa for anemia treatment in hemodialysis patients
    Tadao Akizawa, Yusuke Yamaguchi, Yoshikatsu Majikawa, Michael Reusch · 2020 · Therapeutic Apheresis and Dialysis
  21. Treatment of Anemia in Kidney Disease: Beyond Erythropoietin
    Jay B. Wish · 2021 · Kidney International Reports
  22. Trends in haemoglobin, erythropoietin-stimulating agents and iron use in Swedish chronic kidney disease patients between 2008 and 2013
    Marie Evans, M. Suttorp, Rino Bellocco, Tiny Hoekstra, Abdul Rashid Qureshi, Friedo Wilhelm Dekker, Juan Jesús Carrero · 2015 · Nephrology Dialysis Transplantation
  23. Plasma methemoglobin as a potential biomarker of anemic stress in humans
    Gregory M. T. Hare, Alexander Mu, Alexander D. Romaschin, Albert K.Y. Tsui, Nadine Shehata, William Scott Beattie, C. David Mazer · 2012 · Canadian Journal of Anesthesia/Journal canadien d anesthésie
  24. Management of the Dialysis Patient with Sickle Cell Disease
    Suzanne M. Boyle, Benjamin Jacobs, Farzana A. Sayani, Brenda Hoffman · 2015 · Seminars in Dialysis
  25. Comparative Effectiveness of Two Anemia Management Strategies for Complex Elderly Dialysis Patients
    Yi Zhang, Mae Thamer, James S. Kaufman, Dennis J. Cotter, Miguel Ángel Hernán · 2014 · Medical Care
  26. Assessment and treatment of preoperative anemia: Continuing Professional Development
    Gregory M. T. Hare, James E. Baker, Katerina Pavenski · 2011 · Canadian Journal of Anesthesia/Journal canadien d anesthésie
  27. Treatment of Anaemia with Erythropoiesis-Stimulating Agents in Patients with Chronic Kidney Disease Does Not Lower Mortality and May Increase Cardiovascular Risk: A Meta-Analysis
    José Vinhas, C. Barreto, José Assunção, Leonor Parreira, Álefe Fernandes Vaz · 2012 · Nephron Clinical Practice
  28. Changes in erythropoiesis-stimulating agent (ESA) dosing and haemoglobin levels in US non-dialysis chronic kidney disease patients between 2005 and 2009
    Deborah L. Regidor, William M. McClellan, Reshma Kewalramani, Amit Kumar Sharma, Brian D. Bradbury · 2010 · Nephrology Dialysis Transplantation
  29. Hematocrit and Stroke: A Forgotten and Neglected Link?
    Konstantinos Stavropoulos, Konstantinos P. Imprialos, Chrysoula Boutari, Michael N. Doumas, Sofia Bouloukou · 2017 · Seminars in Thrombosis and Hemostasis
  30. Prevalence of anemia in predialysis chronic kidney disease: Is the study center a significant factor?
    Selma Alagöz, Mevlüt Tamer Dinçer, Necmi Eren, Alev Bakır, Meltem Pekpak, Sinan Trabulus, Nurhan Seyahi · 2020 · PLoS ONE
  31. ESA, Iron Therapy and New Drugs: Are There New Perspectives in the Treatment of Anaemia?
    Lucia Del Vecchio, Roberto Minutolo · 2021 · Journal of Clinical Medicine
  32. Erythropoiesis-Stimulating Agent Treatment in Patients With COVID-19
    Steven N. Fishbane, Jamie S. Hirsch · 2020 · American Journal of Kidney Diseases
  33. Chronic Kidney Disease
    Morgan Erika Grams, Michal L. Melamed · 2025 · Annals of Internal Medicine
  34. A Within-Patient Analysis for Time-Varying Risk Factors of CKD Progression
    Liang Li, Alex R. Chang, Stephen G. Rostand, Lee A. Hebert, Lawrence J. Appel, Brad C. Astor, Michael S. Lipkowitz, Jackson T. Wright, Cynthia A. Kendrick, Xuelei Wang et al. · 2013 · Journal of the American Society of Nephrology
  35. Is it AKI or Nonrecovery of Renal Function That Is Important for Long-Term Outcomes?
    Steven G. Coca · 2013 · Clinical Journal of the American Society of Nephrology
  36. Asymmetric Dimethylarginine Contributes to the Impaired Response to Erythropoietin in CKD-Anemia
    Miyuki Yokoro, Yosuke Nakayama, Sho‐ichi Yamagishi, Ryotaro Ando, Miki Sugiyama, Sakuya Ito, Junko Yano, Kensei Taguchi, Yusuke Kaida, Daisuke Saigusa et al. · 2017 · Journal of the American Society of Nephrology
  37. Cardiovascular Safety and All-Cause Mortality of Methoxy Polyethylene Glycol-Epoetin Beta and Other Erythropoiesis-Stimulating Agents in Anemia of CKD
    Francesco Locatelli, Thierry P. Hannedouche, Steven N. Fishbane, Zoe Morgan, Delphine Oguey, William B. White · 2019 · Clinical Journal of the American Society of Nephrology
  38. Hypoxia-inducible factor prolyl hydroxylase inhibitor in the treatment of anemia in chronic kidney disease
    Yu Kurata, Tetsuhiro Tanaka, Masaomi Nangaku · 2020 · Current Opinion in Nephrology & Hypertension
  39. Effect of hypoxia-inducible factor-prolyl hydroxylase inhibitors on anemia in patients with CKD: a meta-analysis of randomized controlled trials including 2804 patients
    Bin Wang, Qing Yin, Yu‐Chen Han, Min Wu, Zuo‐Lin Li, Yan Tu, Le‐Ting Zhou, Qing Wei, Hong Liu, Ri‐Ning Tang et al. · 2020 · Renal Failure
  40. Vadadustat for anemia in chronic kidney disease patients on peritoneal dialysis: A phase 3 open‐label study in Japan
    Masaomi Nangaku, Kazuoki Kondo, Souichirou Takabe, Kiichiro Ueta, Genki Kaneko, Makiko Otsuka, Yutaka Kawaguchi, Yasuhiro Komatsu · 2020 · Therapeutic Apheresis and Dialysis
  41. Blood Transfusion and Adverse Graft-related Events in Kidney Transplant Patients
    David Massicotte‐Azarniouch, Manish M. Sood, Dean A. Fergusson, Michaël Chassé, Alan T. Tinmouth, Greg A. Knoll · 2021 · Kidney International Reports
  42. New-onset anemia and associated risk of ESKD and death in non-dialysis CKD patients: a multicohort observational study
    Roberto Minutolo, Michele Provenzano, Paolo Chiodini, Silvio Borrelli, Carlo Garofalo, Michele Andreucci, Maria Elena Liberti, Vincenzo Bellizzi, Giuseppe Conte, Luca De Nicola et al. · 2022 · Clinical Kidney Journal
  43. Preclinical neuroprotective actions of xenon and possible implications for human therapeutics: a narrative review
    Mervyn Maze · 2015 · Canadian Journal of Anesthesia/Journal canadien d anesthésie
  44. Anaemia management in patients with chronic kidney disease: T aiwan practice guidelines
    Szu‐Chun Hung, Ko‐Lin Kuo, Der‐Cherng Tarng, Chih‐Cheng Hsu, Kwan‐Dun Wu, Tung‐Po Huang · 2014 · Nephrology
  45. Erythropoietin and Resistant Hypertension in CKD
    Suzanne M. Boyle, Jeffrey S. Berns · 2014 · Seminars in Nephrology
  46. Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease
    Bernardo Rodríguez‐Iturbe, Ricardo Correa‐Rotter · 2010 · Expert Opinion on Pharmacotherapy
  47. A mouse model for an erythropoietin-deficiency anemia
    Brandon M. Zeigler, Janis Vajdos, Wenning Qin, Linda Loverro, Knut Niß · 2010 · Disease Models & Mechanisms
  48. Impact of individual intravenous iron preparations on the differentiation of monocytes towards macrophages and dendritic cells
    Lisa H. Fell, Sarah Seiler-Mußler, Alexander B. Sellier, Björn Rotter, Peter Winter, Martina Sester, Danilo Fliser, Gunnar Henrik Heine, Adam M. Zawada · 2016 · Nephrology Dialysis Transplantation
  49. Androgens and Anemia: Current Trends and Future Prospects
    Ahmed Al‐Sharefi, Azmi Mohammed, Altayeb Abdalaziz, Channa Nalin Jayasena · 2019 · Frontiers in Endocrinology
  50. Factor analysis of various anaerobic power tests.
    J M Manning, CATHRYN R. DOOLY-MANNING, David H. Perrin · 1988 · PubMed
  51. Effect of Medicare Dialysis Payment Reform on Use of Erythropoiesis Stimulating Agents
    Shailender Swaminathan, Vincent Mor, Rajnish Mehrotra, Amal N. Trivedi · 2014 · Health Services Research
  52. Associations of cerebral oxygenation with hemoglobin levels evaluated by near-infrared spectroscopy in hemodialysis patients
    Susumu Ookawara, Kiyonori Ito, Yusuke Sasabuchi, Hideyuki Hayasaka, Masaya Kofuji, Takayuki Uchida, Keita Horigome, Sojiro Imai, Toshiko Akikawa, Noriko Wada et al. · 2020 · PLoS ONE
  53. Better health-related quality of life in kidney transplant patients compared to chronic kidney disease patients with similar renal function
    Jung‐Hwa Ryu, Tai Yeon Koo, Han Ro, Jang‐Hee Cho, Jung Cheol Woong, Kyu Ha Huh, Jae Berm Park, Sik Lee, Seungyeup Han, Jayoun Kim et al. · 2021 · PLoS ONE
  54. Factors Affecting Doses of Roxadustat Versus Darbepoetin Alfa for Anemia in Nondialysis Patients
    Tadao Akizawa, Keiko Tanaka‐Amino, Tetsuro Otsuka, Yusuke Yamaguchi · 2021 · American Journal of Nephrology
  55. Erythropoietin Combined with ACE Inhibitor Prevents Heart Remodeling in 5/6 Nephrectomized Rats Independently of Blood Pressure and Kidney Function
    Nadezda Gut, Grzegorz Piecha, Firas Aldebssi, Sebastian Markus Schaefer, Raffi Bekeredjian, Peter Schirmacher, Eberhard Ritz, Marie-Luise Groß-Weißmann · 2013 · American Journal of Nephrology
  56. Anemia is a predictor of graft loss but not cardiovascular events and all‐cause mortality in renal transplant recipients: follow‐up data from the ALERT study
    Patrick Schjelderup, Dag Olav Dahle, Hallvard Holdaas, Geir Mjøen, G. Nordby, Sadollah Abedini, Alan G. Jardine, Bengt Fellström, My Hanna Sofia Svensson · 2013 · Clinical Transplantation
  57. Inefficacy Interim Monitoring Procedures in Randomized Clinical Trials: The Need to Report
    Edward L. Korn, Boris Freidlin · 2011 · The American Journal of Bioethics
  58. Prevention of Chronic Kidney Disease and Subsequent Effect on Mortality: A Systematic Review and Meta-Analysis
    Usman Khan, Amit X. Garg, Chirag R. Parikh, Steven G. Coca · 2013 · PLoS ONE
  59. An expert opinion on the current treatment of anemia in patients with kidney disease
    Francesco Locatelli, Lucia Del Vecchio · 2012 · Expert Opinion on Pharmacotherapy
  60. Screening for depression: only one piece of the puzzle
    Márta Novák, István Mucsi, David C. Mendelssohn · 2013 · Nephrology Dialysis Transplantation
  61. Differences in Blood Volume Components Between Hyporesponders and Responders to Erythropoietin Alfa: The Heart Failure With Preserved Ejection Fraction (HFPEF) Anemia Trial
    Margarita Borovka, Sergio Luis Teruya, Julissa Alvarez, Stephen T. Helmke, Mathew S. Maurer · 2013 · Journal of Cardiac Failure
  62. Resumen de los ensayos clínicos presentados en las Sesiones Científicas Anuales de la American Heart Association (Orlando, Estados Unidos, 14-18 de noviembre de 2009)
    Leopoldo Pérez de Isla, Antoni Bayés‐Genís, Juan Manuel Sanchís, Magda Heras · 2010 · Revista Española de Cardiología
  63. Patient Safety Issues in CKD: Core Curriculum 2015
    Lee-Ann Wagner, Asha L. Tata, Jeffrey Craig Fink · 2015 · American Journal of Kidney Diseases
  64. Quality of care and practice patterns in anaemia management at specialist kidney clinics in Ireland: a national study
    Austin G. Stack, Ahmed Alghali, Xia Li, John P. Ferguson, Liam F. Casserly, Cornelius J. Cronin, Donal N. Reddan, Wael F. Hussein, Mohamed Elsayed · 2017 · Clinical Kidney Journal
  65. Complexity of intravenous iron nanoparticle formulations: implications for bioequivalence evaluation
    Amy Barton Pai · 2017 · Annals of the New York Academy of Sciences
  66. Hemoglobin concentration and the risk of hemorrhagic and ischemic stroke in patients undergoing hemodialysis: the Q-cohort study
    Ryusuke Yotsueda, Shigeru Tanaka, Masatomo Taniguchi, Kiichiro Fujisaki, Kumiko Torisu, Kosuke Masutani, Hideki Hirakata, Takanari Kitazono, Kazuhiko Tsuruya · 2017 · Nephrology Dialysis Transplantation
  67. Impact of Transferrin Saturation on All-Cause Mortality in Patients on Maintenance Hemodialysis
    Madoka Sato, Norio Hanafusa, Ken Tsuchiya, Hiroshi Kawaguchi, Kosaku Nitta · 2019 · Blood Purification
  68. Kidney disease trials for the 21st century: innovations in design and conduct
    William Guy Herrington, Natalie Staplin, Richard Haynes · 2019 · Nature Reviews Nephrology
  69. Safe and Effective Treatment for Anemic Patients With Chronic Kidney Disease: An Updated Systematic Review and Meta-Analysis on Roxadustat
    Mei Tang, Changyu Zhu, Ting Yan, Yanglin Zhou, Qin Lv, Junlan Chuan · 2021 · Frontiers in Pharmacology
  70. A randomized, double-blind, placebo-controlled study to assess the effect of recombinant human erythropoietin on functional outcomes in anemic, critically ill, trauma subjects: the Long Term Trauma Outcomes Study
    Fred A. Luchette, Michael D. Pasquale, Timothy C. Fabian, Wayne K. Langholff, Marsha Wolfson · 2011 · The American Journal of Surgery
  71. Anaemia and quality of life in chronic kidney disease: a consensus document from the European Anaemia of CKD Alliance
    Indranil Dasgupta, Corinne Isnard Bagnis, Matteo Floris, Hans Furuland, Daniel Gallego Zurro, Loreto Gesualdo, Nathalie Heirman, Roberto Minutolo, Antonello Pani, José María Portolés et al. · 2024 · Clinical Kidney Journal
  72. Erythropoietin for oncology supportive care
    Matthew Stuart McKinney, Murat O. Arcasoy · 2011 · Experimental Cell Research
  73. Erythropoietin and the vascular wall: The controversy continues
    WOLFGANG E. B. JELKMANN, Steve Elliott · 2012 · Nutrition Metabolism and Cardiovascular Diseases
  74. Impact of a Clinical Pharmacy Anemia Management Service on Adherence to Monitoring Guidelines, Clinical Outcomes, and Medication Utilization
    Jenny M. Debenito, Sarah J. Billups, Thu S. Tran, Lea C. Price · 2014 · Journal of Managed Care Pharmacy
  75. Clinical Development Approaches and Statistical Methodologies to Prospectively Assess the Cardiovascular Risk of New Antidiabetic Therapies for Type 2 Diabetes
    Mary Jane Geiger, C R Mehta, J. Rick Turner, Christophe Arbet‐Engels, Stefan Hantel, Boaz Hirshberg, Joerg Koglin, Boaz Mendzelevski, Philip T. Sager, Deborah Shapiro et al. · 2014 · Therapeutic Innovation & Regulatory Science
  76. Association between admission haematocrit and mortality among men with acute ischaemic stroke
    Jason Jonathon Sico, Laura J. Myers, Brenda T. Fenton, John Concato, Linda S. Williams, Dawn M. Bravata · 2018 · Stroke and Vascular Neurology
  77. Effects of hypoxia-inducible factor prolyl hydroxylase inhibitors on iron regulation in non-dialysis-dependent chronic kidney disease patients with anemia: A systematic review and meta-analysis
    Jing Li, Qionghong Xie, Li You, Ningxin Xu, Chuan‐Ming Hao · 2020 · Pharmacological Research
  78. Heart Failure Hospitalization in Adults Receiving Hemodialysis and the Effect of Intravenous Iron Therapy
    Pardeep S. Jhund, Mark Colquhoun Petrie, Michele Robertson, Patrick Barry Mark, Michael Ross MacDonald, Eugene C. Connolly, Stefan D. Anker, Sunil Bhandari, Ken Farrington, Philip A. Kalra et al. · 2021 · JACC Heart Failure
  79. The efficacy and safety of roxadustat for the treatment of anemia in non-dialysis dependent chronic kidney disease patients: An updated systematic review and meta-analysis of randomized clinical trials
    Basel Abdelazeem, Joseph Shehata, Kirellos Said Abbas, Nahla Ahmed El‐Shahat, Bilal Haider Malik, Pramod K. Savarapu, Mostafa M. Eltobgy, Arvind R. Kunadi · 2022 · PLoS ONE
  80. Erythropoietic effects of vadadustat in patients with anemia associated with chronic kidney disease
    Mark J. Koury, Rajiv Agarwal, Glenn Matthew Chertow, Kai‐Uwe Eckardt, Steven N. Fishbane, Tomas Ganz, Volker H. Haase, Mark R. Hanudel, Patrick S. Parfrey, Pablo E. Pérgola et al. · 2022 · American Journal of Hematology
  81. Risk factors for high erythropoiesis stimulating agent resistance index in pre-dialysis chronic kidney disease patients, stages 4 and 5
    Ana Cabrita, Ana Pinho, Anabela Malho Guedes, Elsa Morgado, Marília Faísca, Hermínio Carrasqueira, Ana Paula Silva, Pedro Leão Neves · 2010 · International Urology and Nephrology
  82. Intranasal erythropoietin therapy in nervous system disorders
    Şermin Genç, Zeynep Zadeoğluları, Meryem Gülfem Öner, Kürşad Genç, Murat H. Digicaylioglu · 2010 · Expert Opinion on Drug Delivery
  83. Effectiveness and safety of erythropoiesis-stimulating agent use in the perioperative period
    Diane HD Tran, Gordon TC Wong, Yee Eot Chee, Michael G. Irwin · 2013 · Expert Opinion on Biological Therapy
  84. Cardiorenal Syndrome Type 4: Management
    Anna Clementi, Grazia Maria Virzì, Alessandra Brocca, Massimo de Cal, Giorgio Vescovo, Antonio Raffaele Michele Granata, Claudio Ronco · 2013 · Blood Purification
  85. Erythropoietin Increases Expression and Function of Transient Receptor Potential Canonical 5 Channels
    Ying Liu, Yunfei Xu, Florian Thilo, Ulla Glenert Friis, Boye Lagerbon Jensen, Alexandra Scholze, Junhua Zheng, Martin Tepel · 2011 · Hypertension
  86. Serum Erythropoietin Level and Mortality in Kidney Transplant Recipients
    Miklos Zsolt Molnar, Ádám Gyula Tabák, Ahsan Alam, Maria Eszter Czira, Anna Rudas, Ákos Újszászi, Gabriella Bekő, Márta Novák, Kamyar Kalantar‐Zadeh, Csaba Pal Kovesdy et al. · 2011 · Clinical Journal of the American Society of Nephrology
  87. Interventions for erythropoietin-resistant anaemia in dialysis patients
    Sunil V. Badve, Elaine Beller, Alan Cass, Daniel Peter Francis, Carmel Mary Hawley, Iain C. Macdougall, Vlado Perkovic, David Wayne Johnson · 2013 · Cochrane Database of Systematic Reviews
  88. Practical considerations for iron therapy in the management of anaemia in patients with chronic kidney disease
    Simon D. Roger · 2017 · Clinical Kidney Journal
  89. Obesity may be erythropoietin dose-saving in hemodialysis patients
    Ghada M. El-Kannishy, Abir Farouk Megahed, Mona Tawfik, Ghada El‐Said, Rabab T. Zakaria, Nahed A. Mohamed, Eman M. Taha, Alzhraa A. Ammar, Abeer M. Abd Eltawab, Nagy Sayed‐Ahmed · 2018 · Kidney Research and Clinical Practice
  90. Low hemoglobin at hemodialysis initiation: an international study of anemia management and mortality in the early dialysis period
    Angelo Karaboyas, Hal Morgenstern, Sandra Waechter, Nancy L. Fleischer, Raymond Camille Vanholder, Stefan H. Jacobson, Manish M. Sood, Douglas Earl Schaubel, Masaaki Inaba, Ronald L. Pisoni et al. · 2019 · Clinical Kidney Journal
  91. Safety and effectiveness of metformin in patients with reduced renal function: a systematic review
    Orloff, Jeremy, Min, Jea Young, Mushlin, Alvin, Flory, James · 2021 · Diabetes, Obesity and Metabolism
  92. Cardiovascular events in chronic dialysis patients: emphasizing the importance of vascular disease prevention
    Kosmas I. Paraskevas, Ioannis Kotsikoris, Sotirios A. Koupidis, Alexandros A. Tzovaras, Dimitri P. Mikhailidis · 2010 · International Urology and Nephrology
  93. Clinical Factors and the Decision to Transfuse Chronic Dialysis Patients
    Cynthia B. Whitman, Sanatan Shreay, Matthew D. Gitlin, Martijn G.H. van Oijen, Brennan Mason Ross Spiegel · 2013 · Clinical Journal of the American Society of Nephrology
  94. Hypoxia-Inducible Factor Stabilizers: a New Avenue for Reducing BP While Helping Hemoglobin?
    Farhanah Yousaf, Bruce Spinowitz · 2016 · Current Hypertension Reports
  95. TP0463518, a Novel Prolyl Hydroxylase Inhibitor, Specifically Induces Erythropoietin Production in the Liver
    Sota Kato, Nagahiro Ochiai, Hiroki Takano, Fusayo Io, Noriko Takayama, Hiroko Koretsune, Ei-ichi Kunioka, Saeko Uchida, Koji Yamamoto · 2019 · Journal of Pharmacology and Experimental Therapeutics
  96. Erythropoietin is a major regulator of thrombopoiesis in thrombopoietin-dependent and -independent contexts
    Salima Hacein‐Bey‐Abina, Machadiya Estienne, Stéphanie Bessoles, Hamid Echchakir, Magali Pederzoli-Ribeil, Andrada Chiron, Lydia Aldaz-Carroll, Valentin Leducq, Yanyan Zhang, Michèle Souyri et al. · 2020 · Experimental Hematology
  97. Molidustat for the treatment of renal anaemia in patients with non-dialysis-dependent chronic kidney disease: design and rationale of two phase III studies
    Hiroyasu Yamamoto, Megumi Taguchi, Yoshimi Matsuda, Kazuma Iekushi, Takashi Yamada, Tadao Akizawa · 2019 · BMJ Open
  98. Hyporesponsiveness to erythropoiesis-stimulating agent in non-dialysis-dependent CKD patients: The BRIGHTEN study
    Ichiei Narita, Terumasa Hayashi, Shoichi Maruyama, Takao Masaki, Masaomi Nangaku, Tomoya Nishino, Hiroshi Satō, Tadashi Sofue, Takashi Wada, Enyu Imai et al. · 2022 · PLoS ONE
  99. Critical appraisal of randomized controlled trials of anemia correction in patients with renal failure
    Patrick S. Parfrey · 2010 · Current Opinion in Nephrology & Hypertension
  100. Anemia management in chronic kidney disease: Intravenous iron steps forward
    Daniel W. Coyne, Michael Auerbach · 2010 · American Journal of Hematology